Advagene Biopharma Co., Ltd.(TW:6709)
NT$20.70+0.05 (+0.24%)
TW:6709
Advagene Biopharma Co., Ltd. financials statements
NT$20.70
At close:+0.05 (+0.24%)
Advagene Biopharma Co., Ltd. (6709) Ratios
Advagene Biopharma Co., Ltd. Ratios
TW:6709's free cash flow for Q2 2026 was NT$-57.96M. For the 2026 fiscal year, TW:6709's free cash flow was decreased by NT$-533.00K and operating cash flow was NT$-57.42M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 13.69 | 31.63 | 18.37 | 14.94 | 29.50 |
| Quick Ratio | 13.69 | 31.63 | 18.37 | 14.94 | 29.50 |
| Cash Ratio | 4.76 | 7.43 | 8.18 | 2.14 | 1.73 |
| Solvency Ratio | -4.64 | -5.76 | -10.05 | -11.76 | -7.84 |
| Operating Cash Flow Ratio | -5.51 | -9.94 | -9.75 | -12.98 | -8.12 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -93.82 | -89.31 | -194.92 | -119.75 |
| Net Current Asset Value | NT$ 144.75M | NT$ 213.16M | NT$ 138.44M | NT$ 116.74M | NT$ 233.16M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.03 | 0.01 | 0.02 | 0.02 |
| Debt-to-Equity Ratio | 0.03 | 0.03 | 0.01 | 0.02 | 0.02 |
| Debt-to-Capital Ratio | 0.03 | 0.03 | 0.01 | 0.02 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.05 | 1.06 | 1.07 | 1.04 |
| Debt Service Coverage Ratio | -392.74 | -74.21 | -88.38 | -166.19 | -123.31 |
| Interest Coverage Ratio | -405.25 | -469.03 | -2592.67 | -1479.14 | -743.51 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.07 | 0.12 | 0.02 | 0.05 | 0.09 |
| Net Debt to EBITDA | 0.75 | 0.69 | 0.80 | 0.14 | 0.12 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 96.29% | 98.02% | 98.69% | 98.80% | 98.16% |
| Return on Assets (ROA) | -41.01% | -29.90% | -62.26% | -84.05% | -35.59% |
| Return on Equity (ROE) | -44.85% | -31.48% | -65.81% | -89.84% | -37.14% |
| Return on Capital Employed (ROCE) | -45.78% | -31.46% | -66.69% | -90.48% | -37.45% |
| Return on Invested Capital (ROIC) | -45.40% | -31.18% | -66.27% | -89.19% | -37.18% |
| Return on Tangible Assets | -41.01% | -29.90% | -62.26% | -90.35% | -36.87% |
| Earnings Yield | -4.10% | -6.18% | -7.17% | -8.06% | -3.96% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 1.50 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -243.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 243.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.08 | -1.29 | -1.54 | -2.22 | -1.37 |
| Free Cash Flow Per Share | -1.12 | -1.30 | -1.54 | -2.42 | -1.38 |
| Dividend Paid and CapEx Coverage Ratio | -27.78 | -148.41 | 0.00 | -10.71 | -128.94 |
| Capital Expenditure Coverage Ratio | -27.78 | -148.41 | 0.00 | -10.71 | -128.94 |
| Operating Cash Flow Coverage Ratio | -16.14 | -10.76 | -89.31 | -42.60 | -15.27 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -3.98% | -6.33% | -6.05% | -8.14% | -2.89% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -24.39 | -16.18 | -13.93 | -12.41 | -25.33 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 10.94 | 5.09 | 9.18 | 11.15 | 9.38 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -25.11 | -15.79 | -16.54 | -12.29 | -34.59 |
| Price-to-Operating Cash Flow Ratio | -26.01 | -15.90 | -16.54 | -13.43 | -34.86 |
| Price-to-Earnings Growth (PEG) Ratio | 2.58 | 0.53 | 0.59 | -0.45 | -1.28 |
| Enterprise Value Multiple | -23.49 | -16.05 | -15.24 | -13.62 | -27.49 |
| Enterprise Value | 1.61B | 1.08B | 1.22B | 1.45B | 2.33B |
| EV to EBITDA | -23.49 | -16.05 | -15.24 | -13.62 | -27.49 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -24.33 | -15.14 | -15.71 | -12.16 | -34.45 |
| EV to Operating Cash Flow | -25.21 | -15.25 | -15.71 | -13.29 | -34.71 |
| Tangible Book Value Per Share | 2.56 | 4.03 | 2.78 | 2.47 | 4.89 |
| Shareholders’ Equity Per Share | 2.56 | 4.03 | 2.78 | 2.67 | 5.07 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.15 | -1.27 | -1.83 | -2.40 | -1.88 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.96 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.94 | 1.02 | 0.84 | 0.92 | 0.72 |
Currency in TWD
